ArticleEvolutionary applications2022
Co-evolutionary adaptations of
Article in Evolutionary applications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Global epidemiological and genetic characteristics of carbapenem-resistantMicrobiology spectrum · 2026Article
- A newly identified sequence type: genomic and pathogenic profiling of the highly virulentFrontiers in cellular and infection microbiology · 2026Article
- Characterization of the virulence shaping and adaptability in the methicillin-resistantmSystems · 2025Article
- Phenotypic and genotypic characterization of clinical carbapenem-resistantMicrobiology spectrum · 2025Article
- Discovery of novel BfmR inhibitors restoring carbapenem susceptibility against carbapenem-resistantEmerging microbes & infections · 2024Article
- Gram-Negative ESKAPE Bacteria Surveillance in COVID-19 Pandemic Exposes High-Risk Sequence Types ofPathogens (Basel, Switzerland) · 2024Article
- Characteristics of OralInfection and drug resistance · 2024Article
- A mathematician's guide to plasmids: an introduction to plasmid biology for modellers.Microbiology (Reading, England) · 2023Review
- Article
- Nomogram for predicting 90-day mortality in patients withThe Journal of international medical research · 2023Article
- Co-evolutionary adaptations ofEvolutionary applications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 3 countries.
Funding
Abstract
OXA-23 is the predominant carbapenemase in carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.